208 related articles for article (PubMed ID: 38222315)
1. Silibinin, a potential fasting mimetic, inhibits hepatocellular carcinoma by triggering extrinsic apoptosis.
Xiao B; Jiang Y; Yuan S; Cai L; Xu T; Jia L
MedComm (2020); 2024 Jan; 5(1):e457. PubMed ID: 38222315
[TBL] [Abstract][Full Text] [Related]
2. Autophagy and glycolysis independently attenuate silibinin-induced apoptosis in human hepatocarcinoma HepG2 and Hep3B cells.
Yang J; Sun Y; Xu F; Liu W; Hayashi T; Mizuno K; Hattori S; Fujisaki H; Ikejima T
Hum Exp Toxicol; 2021 Dec; 40(12):2048-2062. PubMed ID: 34053323
[TBL] [Abstract][Full Text] [Related]
3. Role of AMPK signaling in mediating the anticancer effects of silibinin in esophageal squamous cell carcinoma.
Li J; Li B; Xu WW; Chan KW; Guan XY; Qin YR; Lee NP; Chan KT; Law S; Tsao SW; Cheung AL
Expert Opin Ther Targets; 2016; 20(1):7-18. PubMed ID: 26568207
[TBL] [Abstract][Full Text] [Related]
4. Silibinin sensitizes TRAIL-mediated apoptosis by upregulating DR5 through ROS-induced endoplasmic reticulum stress-Ca
Dilshara MG; Jayasooriya RGPT; Molagoda IMN; Jeong JW; Lee S; Park SR; Kim GY; Choi YH
Oncotarget; 2018 Feb; 9(12):10324-10342. PubMed ID: 29535810
[TBL] [Abstract][Full Text] [Related]
5. Silibinin triggers apoptotic signaling pathways and autophagic survival response in human colon adenocarcinoma cells and their derived metastatic cells.
Kauntz H; Bousserouel S; Gossé F; Raul F
Apoptosis; 2011 Oct; 16(10):1042-53. PubMed ID: 21779837
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of Silibinin combined with doxorubicin in hepatocellular carcinoma; an in vivo study.
Li WG; Wang HQ
J BUON; 2016; 21(4):917-924. PubMed ID: 27685914
[TBL] [Abstract][Full Text] [Related]
7. Silibinin induced apoptosis of human epidermal cancer A431 cells by promoting mitochondrial NOS.
Yu Y; Li LF; Tao J; Zhou XM; Xu C
Free Radic Res; 2019 Jul; 53(7):714-726. PubMed ID: 30947567
[TBL] [Abstract][Full Text] [Related]
8. Silymarin inhibits growth and causes regression of established skin tumors in SENCAR mice via modulation of mitogen-activated protein kinases and induction of apoptosis.
Singh RP; Tyagi AK; Zhao J; Agarwal R
Carcinogenesis; 2002 Mar; 23(3):499-510. PubMed ID: 11895866
[TBL] [Abstract][Full Text] [Related]
9. Silibinin activates AMP-activated protein kinase to protect neuronal cells from oxygen and glucose deprivation-re-oxygenation.
Xie Z; Ding SQ; Shen YF
Biochem Biophys Res Commun; 2014 Nov; 454(2):313-9. PubMed ID: 25450395
[TBL] [Abstract][Full Text] [Related]
10. Silibinin efficacy against human hepatocellular carcinoma.
Varghese L; Agarwal C; Tyagi A; Singh RP; Agarwal R
Clin Cancer Res; 2005 Dec; 11(23):8441-8. PubMed ID: 16322307
[TBL] [Abstract][Full Text] [Related]
11. Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells.
Gu HR; Park SC; Choi SJ; Lee JC; Kim YC; Han CJ; Kim J; Yang KY; Kim YJ; Noh GY; No SH; Jeong JH
Clin Mol Hepatol; 2015 Mar; 21(1):49-59. PubMed ID: 25834802
[TBL] [Abstract][Full Text] [Related]
12. Effects and mechanisms of silibinin on human hepatocellular carcinoma xenografts in nude mice.
Cui W; Gu F; Hu KQ
World J Gastroenterol; 2009 Apr; 15(16):1943-50. PubMed ID: 19399925
[TBL] [Abstract][Full Text] [Related]
13. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis.
Tyagi AK; Singh RP; Agarwal C; Chan DC; Agarwal R
Clin Cancer Res; 2002 Nov; 8(11):3512-9. PubMed ID: 12429642
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of GSK-3β activity suppresses HCC malignant phenotype by inhibiting glycolysis via activating AMPK/mTOR signaling.
Fang G; Zhang P; Liu J; Zhang X; Zhu X; Li R; Wang H
Cancer Lett; 2019 Oct; 463():11-26. PubMed ID: 31404613
[TBL] [Abstract][Full Text] [Related]
15. Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT.
Mao J; Yang H; Cui T; Pan P; Kabir N; Chen D; Ma J; Chen X; Chen Y; Yang Y
Eur J Pharmacol; 2018 Aug; 832():39-49. PubMed ID: 29782854
[TBL] [Abstract][Full Text] [Related]
16. Hispidulin inhibits hepatocellular carcinoma growth and metastasis through AMPK and ERK signaling mediated activation of PPARγ.
Han M; Gao H; Ju P; Gao MQ; Yuan YP; Chen XH; Liu KL; Han YT; Han ZW
Biomed Pharmacother; 2018 Jul; 103():272-283. PubMed ID: 29656183
[TBL] [Abstract][Full Text] [Related]
17. Silibinin relieves UVB-induced apoptosis of human skin cells by inhibiting the YAP-p73 pathway.
Liu WW; Wang F; Li C; Song XY; Otkur W; Zhu YY; Hayashi T; Mizuno K; Hattori S; Fujisaki H; Ikejima T
Acta Pharmacol Sin; 2022 Aug; 43(8):2156-2167. PubMed ID: 34912007
[TBL] [Abstract][Full Text] [Related]
18. Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells.
Agarwal C; Singh RP; Dhanalakshmi S; Tyagi AK; Tecklenburg M; Sclafani RA; Agarwal R
Oncogene; 2003 Nov; 22(51):8271-82. PubMed ID: 14614451
[TBL] [Abstract][Full Text] [Related]
19. Adenine inhibits growth of hepatocellular carcinoma cells via AMPK-mediated S phase arrest and apoptotic cascade.
Su WW; Huang JY; Chen HM; Lin JT; Kao SH
Int J Med Sci; 2020; 17(5):678-684. PubMed ID: 32210718
[No Abstract] [Full Text] [Related]
20. Hispidulin induces ER stress-mediated apoptosis in human hepatocellular carcinoma cells in vitro and in vivo by activating AMPK signaling pathway.
Han M; Gao H; Xie J; Yuan YP; Yuan Q; Gao MQ; Liu KL; Chen XH; Han YT; Han ZW
Acta Pharmacol Sin; 2019 May; 40(5):666-676. PubMed ID: 30218072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
